Center for Drug Evaluation and Research growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split. In its original form, CDER was composed of six offices: Management, Compliance, Drug Standards, Drug Evaluation I, Drug Evaluation II, Epidemiology and Biostatistics, and Research Resources. The Division of Antiviral Products was added in 1989 under Drug Evaluation II due to the large amount of drugs proposed for treating AIDS. The Office of Generic Drugs was also formed. In 2002,
Crude drug The study of form of a crude drug is MORPHOLOGY, while description of the form is MORPHOGRAPHY. However, it should be noted that color, shape and size of crude drugs as described in official books should only be considered as guidelines and may vary depending upon several factors. For example, color of the crude drug may fade if it gets exposed to sunlight for very long duration or if, the drug is not stored properly. Depending upon the condition under which the drug is growing or cultivated, i.e., availability of proper irrigation, fertilizers or even high temperature, may influence the